Manish Goel

Manish Goel - SEBI Registered Research Analyst

About Manish Goel

SEBI Registered Research Analyst • Chartered Accountant

377 Articles Published

Manish Goel is a Chartered Accountant, SEBI Registered Research Analyst, and founder of Manish Goel PMS. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

May 19, 2026
Infographic: The Conjunction Fallacy with a 2x2 grid—top-left 'Lucky', top-right 'DISCIPLINED INVESTOR', bottom-left 'Confused', bottom-right 'BIAS-TRAPPED'.

The Conjunction Fallacy: Tversky & Kahneman’s 1983 ‘Linda Problem’ — Why Indian Investors Believe Elaborate Multi-Leg Bull Theses Are More Probable Than Simple Ones

Tversky & Kahneman's 1983 conjunction fallacy explains why Indian retail investors judge five-leg bull stories as more probable than one-leg theses — and how single-leg corporate behaviour like Titan Biotech Ltd's audited FY25 numbers illustrates the opposite discipline.
May 19, 2026
Infographic titled 'James Montier’s Modified C-Score' with a horizontal bar chart of FY20–FY25, highlighting FY25 in green. The chart shows stacked values ending values like 3.2, 2.8, 2.1, 1.6, 1.3, and 1.1.

James Montier’s Modified C-Score: The 6-Variable Cooking-the-Books Detector That Complements Beneish M-Score and Piotroski F-Score

James Montier's Modified C-Score is a six-variable forensic detector for accounting manipulation. We decode all six variables, contrast a disciplined manufacturer with a generic red-flag profile, and show how Titan Biotech FY25's audited numbers score 0/6 — an educational illustration only, not a buy/sell recommendation.
May 19, 2026
Website hero with title 'Capacity to Suffer' and subtitle, plus a two-by-two grid: Trader (gray), Drift (light gray), Compounder (green), Speculator (orange).

Capacity to Suffer: Tom Russo’s Doctrine on Why Long-Term Compounders Tolerate Short-Term Reported-Earnings Drag

Tom Russo's Capacity to Suffer concept names the rarest corporate trait: management willingness to depress today's reported earnings to fund tomorrow's moat. Illustrated with Titan Biotech FY25 audited markers.
May 18, 2026
Infographic titled The Bias Blind Spot with four labeled blocks: Lucky (grey), Disciplined Investor (green), Confused (light grey), Bias-Trapped (orange) on a dark blue page.

The Bias Blind Spot: Pronin, Lin & Ross (2002)

Pronin, Lin & Ross's 2002 Stanford research on the meta-bias that hides every other cognitive error — why education makes the blind spot worse, the SEBI F&O data that shows ₹1.81 lakh crore of Indian retail losses for what they really are, the six external-structure counter-measures, and how Titan Biotech's FY25 governance architecture (4 of 11 independent directors, 14 board meetings, CFO/OP at 103%, contingent liabilities down 39.7%) illustrates the institutional version of Munger's iron prescription.
+91-7380122211